Fig. 10

a Schematic of the security assessment process in vivo. PBS (100 μL) or GPRPP-Y8U@P (1 mg/mL, 100 μL) was administrated by tail vein injection for a week. During this period, the weight change were recorded to reflect the impact of hematologic toxicity. Afterward, a tail bleeding assay was performed to assess the model mice’ hemostatic function and bleeding risk. b The daily change of weight. c, d The bleeding time and volume in the tail bleeding assay. e–g Some biochemical indicators (Fg: fibrinogen, TBil: total bilirubin, TP: total protein)